EE200300422A - GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks - Google Patents

GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks

Info

Publication number: EE200300422A
Authority: EE; Estonia
Prior art keywords: estrogen; agonists; vitamin; treatment; combination
Prior art date: 2001-03-01

Application number

EEP200300422A

Other languages

English (en)

Estonian (et)

Inventor

Villalobos Anabella

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-01

Filing date

2002-02-20

Publication date

2004-02-16

2002-02-20 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-02-16 Publication of EE200300422A publication Critical patent/EE200300422A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Virology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Other In-Based Heterocyclic Compounds (AREA)

EEP200300422A 2001-03-01 2002-02-20 GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks EE200300422A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27256601P	2001-03-01	2001-03-01
PCT/IB2002/000515 WO2002069948A1 (en)	2001-03-01	2002-02-20	Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Publications (1)

Publication Number	Publication Date
EE200300422A true EE200300422A (et)	2004-02-16

Family

ID=23040351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300422A EE200300422A (et)	2001-03-01	2002-02-20	GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks

Country Status (33)

Country	Link
US (2)	US20020193360A1 (xx)
EP (1)	EP1363606A1 (xx)
JP (1)	JP2004527500A (xx)
KR (1)	KR20030076717A (xx)
CN (1)	CN1494422A (xx)
AP (1)	AP2002002465A0 (xx)
AR (1)	AR033425A1 (xx)
BG (1)	BG108131A (xx)
BR (1)	BR0207802A (xx)
CA (1)	CA2439581A1 (xx)
CR (1)	CR7059A (xx)
CZ (1)	CZ20032338A3 (xx)
DO (1)	DOP2002000345A (xx)
EA (1)	EA200300854A1 (xx)
EC (1)	ECSP034759A (xx)
EE (1)	EE200300422A (xx)
GT (1)	GT200200039A (xx)
HU (1)	HUP0303448A3 (xx)
IL (1)	IL157465A0 (xx)
IS (1)	IS6905A (xx)
MA (1)	MA26999A1 (xx)
MX (1)	MXPA03007834A (xx)
NO (1)	NO20033821L (xx)
NZ (1)	NZ527397A (xx)
OA (1)	OA12554A (xx)
PA (1)	PA8540701A1 (xx)
PE (1)	PE20020927A1 (xx)
PL (1)	PL364081A1 (xx)
SK (1)	SK10752003A3 (xx)
TN (1)	TNSN02018A1 (xx)
UY (1)	UY27188A1 (xx)
WO (1)	WO2002069948A1 (xx)
ZA (1)	ZA200306193B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080004332A1 (en) *	2002-03-07	2008-01-03	Alkon Daniel L	Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) *	2002-03-07	2005-03-24	Daniel Alkon	Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en)	2002-03-07	2004-11-30	Blanchette Rockefeller Neurosciences Institute	Methods for Alzheimer's Disease treatment and cognitive enhancement
WO2005000806A2 (en)	2003-06-10	2005-01-06	Georgetown University	Ligands for nicotinic acetylcholine receptors, and methods of making and using them
TW201206425A (en)	2004-05-18	2012-02-16	Brni Neurosciences Inst	Treatment of depressive disorders
US8510055B2 (en)	2005-08-03	2013-08-13	The Johns Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
EP2682481A3 (en) *	2005-08-03	2014-09-17	The Johns-Hopkins University	Methods for characterizing and treating cognitive impairment in aging and disease
DK2032987T3 (en)	2006-05-22	2016-04-25	Univ Leland Stanford Junior	Pharmacological treatment of Cognitive impairment
AU2013202426B2 (en) *	2006-10-16	2015-08-06	Bionomics Limited	Novel anxiolytic compounds
EP2540722B1 (en) *	2006-10-16	2016-06-08	Bionomics Limited	Novel anxiolytic compounds
US10954231B2 (en)	2006-10-16	2021-03-23	Bionomics Limited	Anxiolytic compounds
CA2674773A1 (en)	2007-02-09	2008-08-21	Blanchette Rockefeller Neurosciences Institute	Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
EP2268639A2 (en) *	2008-05-22	2011-01-05	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) *	2008-06-19	2009-12-24	Vinod Kumar Kansal	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US10206921B2 (en) *	2009-06-03	2019-02-19	The Regents Of The University Of California	Methods and compositions for treating a subject for central nervous system (CNS) injury
RU2012102052A (ru) *	2009-06-22	2013-11-20	Тева Фармасьютикал Индастриз Лтд.	Твердые формы солей варениклина и способы их получения
WO2012068161A1 (en)	2010-11-15	2012-05-24	Agenebio, Inc.	Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012116410A1 (en) *	2011-03-02	2012-09-07	Bionomics Limited	Methods of treating a disease or condition of the central nervous system
WO2012116415A1 (en)	2011-03-02	2012-09-07	Bionomics Limited	Novel small-molecules as therapeutics
AU2012253237B2 (en)	2011-05-12	2015-09-24	Bionomics Limited	Methods for preparing naphthyridines
MX381561B (es)	2013-12-20	2025-03-12	Agenebio Inc	Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo.
CN113264939A (zh)	2015-06-19	2021-08-17	艾吉因生物股份有限公司	用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt)	2016-12-19	2019-11-26	Agenebio, Inc.	derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
EA202190076A1 (ru)	2018-06-19	2021-09-22	Эйджинбайо, Инк.	Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
CN116008442B (zh) *	2023-03-27	2023-06-30	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116077459B (zh) *	2023-04-10	2023-07-07	上海赛默罗生物科技有限公司	α5-GABAA受体调节剂的胶囊剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK2162000A3 (en) *	1997-08-25	2001-03-12	Neurogen Corp	Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
AU5289600A (en) *	1999-05-25	2000-12-12	Neurogen Corporation	4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands

2002
- 2002-02-20 NZ NZ527397A patent/NZ527397A/en unknown
- 2002-02-20 JP JP2002569125A patent/JP2004527500A/ja active Pending
- 2002-02-20 CN CNA028058046A patent/CN1494422A/zh active Pending
- 2002-02-20 OA OA1200300213A patent/OA12554A/en unknown
- 2002-02-20 SK SK1075-2003A patent/SK10752003A3/sk not_active Application Discontinuation
- 2002-02-20 HU HU0303448A patent/HUP0303448A3/hu unknown
- 2002-02-20 BR BR0207802-3A patent/BR0207802A/pt not_active IP Right Cessation
- 2002-02-20 EE EEP200300422A patent/EE200300422A/xx unknown
- 2002-02-20 PL PL02364081A patent/PL364081A1/xx not_active Application Discontinuation
- 2002-02-20 CZ CZ20032338A patent/CZ20032338A3/cs unknown
- 2002-02-20 WO PCT/IB2002/000515 patent/WO2002069948A1/en not_active Ceased
- 2002-02-20 EA EA200300854A patent/EA200300854A1/ru unknown
- 2002-02-20 KR KR10-2003-7011366A patent/KR20030076717A/ko not_active Ceased
- 2002-02-20 CA CA002439581A patent/CA2439581A1/en not_active Abandoned
- 2002-02-20 IL IL15746502A patent/IL157465A0/xx unknown
- 2002-02-20 MX MXPA03007834A patent/MXPA03007834A/es unknown
- 2002-02-20 EP EP02700509A patent/EP1363606A1/en not_active Withdrawn
- 2002-02-26 US US10/083,743 patent/US20020193360A1/en not_active Abandoned
- 2002-02-26 DO DO2002000345A patent/DOP2002000345A/es unknown
- 2002-02-26 PE PE2002000157A patent/PE20020927A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100693A patent/AR033425A1/es not_active Application Discontinuation
- 2002-02-27 UY UY27188A patent/UY27188A1/es not_active Application Discontinuation
- 2002-02-27 GT GT200200039A patent/GT200200039A/es unknown
- 2002-02-28 AP APAP/P/2002/002465A patent/AP2002002465A0/en unknown
- 2002-02-28 PA PA20028540701A patent/PA8540701A1/es unknown
- 2002-02-28 TN TNTNSN02018A patent/TNSN02018A1/fr unknown
2003
- 2003-08-07 IS IS6905A patent/IS6905A/is unknown
- 2003-08-11 ZA ZA200306193A patent/ZA200306193B/en unknown
- 2003-08-19 MA MA27286A patent/MA26999A1/fr unknown
- 2003-08-25 BG BG108131A patent/BG108131A/xx unknown
- 2003-08-25 CR CR7059A patent/CR7059A/es not_active Application Discontinuation
- 2003-08-28 NO NO20033821A patent/NO20033821L/no not_active Application Discontinuation
- 2003-09-01 EC EC2003004759A patent/ECSP034759A/es unknown
- 2003-12-02 US US10/727,934 patent/US20040082555A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0303448A2 (hu)	2004-01-28
MXPA03007834A (es)	2003-12-08
EP1363606A1 (en)	2003-11-26
ECSP034759A (es)	2003-10-28
GT200200039A (es)	2002-11-21
OA12554A (en)	2006-06-07
UY27188A1 (es)	2002-10-31
IL157465A0 (en)	2004-03-28
PE20020927A1 (es)	2002-10-30
US20020193360A1 (en)	2002-12-19
EA200300854A1 (ru)	2004-02-26
IS6905A (is)	2003-08-07
CN1494422A (zh)	2004-05-05
MA26999A1 (fr)	2004-12-20
NO20033821D0 (no)	2003-08-28
NO20033821L (no)	2003-09-10
NZ527397A (en)	2005-05-27
TNSN02018A1 (fr)	2005-12-23
PL364081A1 (en)	2004-12-13
AR033425A1 (es)	2003-12-17
PA8540701A1 (es)	2002-09-30
CZ20032338A3 (cs)	2004-08-18
DOP2002000345A (es)	2002-12-15
BR0207802A (pt)	2004-03-09
BG108131A (en)	2004-09-30
AP2002002465A0 (en)	2002-06-30
HUP0303448A3 (en)	2005-05-30
SK10752003A3 (sk)	2004-08-03
ZA200306193B (en)	2004-08-11
CR7059A (es)	2004-03-10
US20040082555A1 (en)	2004-04-29
JP2004527500A (ja)	2004-09-09
WO2002069948A1 (en)	2002-09-12
CA2439581A1 (en)	2002-09-12
KR20030076717A (ko)	2003-09-26

Publication	Publication Date	Title
EE200300422A (et)	2004-02-16	GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks
DK1110949T3 (da)	2003-11-24	EP4-receptorselektive agonister, som er anvendelige ved behandling af osteoporose
BR0117199B1 (pt)	2010-09-08	dispositivo para realização de osteosìntese.
DK1144388T3 (da)	2010-05-25	Acyl-derivater, som behandler VLA-4-relaterede lidelser
EE200300246A (et)	2003-10-15	EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
NO20030213D0 (no)	2003-01-16	Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
DK1497293T3 (da)	2008-09-15	(1,4)Diazepino(6,7,1-ij)quinolinderivater som antipsykotiske og antiobesitetsmidler
DE60333751D1 (de)	2010-09-23	Kommunikationsverfahren, kommunikationssystem und kommunikationseinrichtung
DE602004012891D1 (de)	2008-05-15	Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
ATE384697T1 (de)	2008-02-15	2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
DE60219744D1 (de)	2007-06-06	Trainingsgerät für Passagiersitze
AR028579A1 (es)	2003-05-14	Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica
GB0322983D0 (en)	2003-11-05	Sampling kits, devices and uses thereof
DE602005014040D1 (de)	2009-06-04	Transferträgerelement, Zwischentransferelement, und diese verwendende Bilderzeugungsvorrichtung
FI20045375A0 (fi)	2004-10-06	Kova yhteysvastuunvaihtomenetelmä, kontrolleri ja tiedonvälitysjärjestelmä
DE60039652D1 (de)	2008-09-11	Heizwiderstände, Heizwiderstände, die für keramischen Heizelementen bestimmt sind, und keramische Heizelemente, die diegleichen benützen
BRPI0310056A2 (pt)	2016-06-28	método de transpiração térmica, recipiente de transpiração térmica e aparelho de transpiração térmica utilizados para o mesmo
BRPI0613443A2 (pt)	2016-11-16	método para tratamento de superfície de um objeto, rolo de fio, e, uso do método"
ES1049094Y (es)	2002-03-16	Dispositivo para la formacion de chaflanes en encofrados.
ES1048055Y (es)	2002-04-01	Dispositivo para la aplicacion de tintes capilares.
ES1049121Y (es)	2002-03-16	Dispositivo de sustentacion perfeccionado para cortinas y similares.
ES1050258Y (es)	2002-07-01	Tapon con caperuza, perfeccionado
BR8101479Y1 (pt)	2012-01-10	aparelho para testes de carbonatação em latas.
BR8102921Y1 (pt)	2012-05-15	disposição introduzida em clipe articulado graduado para óculos de segurança.
ITPD20030313A1 (it)	2005-06-30	Apparechiatura per il controllo della somministrazione di test di tipo cognitivo, psicofisico e simili